Previous 10 | Next 10 |
home / stock / huma / huma articles
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session. The company announced its third-quarter earnings date...
U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday. Shares of Fifth Third Bancorp (NASDAQ:FITB) rose during Friday...
U.S. stocks were lower, with the Nasdaq Composite falling over 50 points on Thursday. Shares of Ally Financial Inc. (NYSE:ALLY) rose sharply during...
-Biologics License Application (BLA) for HAV™ Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indicat...
The CNN Money Fear and Greed index showed a slight increase in the overall market sentiment on Thursday. U.S. stocks closed higher on Thursday...
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univer...
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-tha...
Humacyte Inc (NASDAQ:HUMA) shares are trading lower by 29.2% to $3.08 during Friday’s session after the company announced pricing of a $40.2...
DURHAM, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing univer...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...